•  
  •  
 

Abstract

Serous uterine endometrial cancer is a lethal disease for which new therapeutic regimens are urgently needed. Combinations of chemotherapeutic agents and small molecule growth factor inhibitors have demonstrated activity in cancers from other sites. Our objective was to determine whether such a combination using Paclitaxel and Gefitinib could be active in serous endometrial cancer cells.

Keywords

Paclitaxel, Gefitinib, endometrial cancer, mitotic catastrophe, p38, p53

Submission Type

Article

Rights

Copyright © Xiangbing Meng, Laura L. Laidler, Lina Albitar, Anna M. Holmes, Donghai Dai, Thomas E. Buekers, David P. Bender, Kimberly K. Leslie, 2011.

Creative Commons License


This work is licensed under a Creative Commons Attribution 3.0 License.